The Omnipod® 5 Knowledge Hub
Tools to help you and your patients get started with Omnipod®
Help your patients get the most from their Omnipod® 5 Automated Insulin Delivery system with these downloadable resources, guides, videos and more.
Omnipod® 5 Guides
- Omnipod® 5 User Guide: (View guide)
Getting started on Omnipod® 5:
Thank you for choosing to prescribe the Omnipod® 5 Automated Insulin Delivery system, integrated with Dexcom G6 and Dexcom G7**. The additional sensor integration of FreeStyle Libre 2 Plus** will be available for your patients in 2025.
For more information to support your patients starting successfully on Omnipod 5 click on the link below.
If you require a hard copy of the Omnipod® 5 User Guide give us a call at 1800 954 074 or +61 272 084 352. We'll be happy to help you.
Getting started on the Omnipod® 5 Automated Insulin Delivery System
Frequently Asked Questions
We have heard from many people in the community regarding their interest in the Omnipod® 5 system. Here are answers to some of the community’s most frequently asked questions.
Omnipod® 5: The Algorithm Explained
SmartAdjust™ Technology
SmartAdjust™ Technology automatically increases, decreases, or pauses insulin delivery, every five minutes, to your personal needs which may help to prevent against highs and lows1,2 . Watch these videos to learn more.
Initialisation: Learn how SmartAdjust™ works and tips for initialisation with your patients.
Optimisation: Once your patient has successfully started using the system, learn how to optimise it for best results.
Additional Resources
Omnipod® 5 Automated Insulin Delivery System
Meet the next generation Omnipod 5 Automated Insulin Delivery System. Read more.
Multicenter Trial of a Tubeless System
Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycaemic Targets in Paediatric and Adult Participants With Type 1 Diabetes. Read more.
Safety and Glycaemic Outcomes
Safety and Glycaemic Outcomes with a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Read more.
Omnipod® 5 Webinars
Join our monthly virtual webinars to get a comprehensive overview of Omnipod® 5 and gain insight on best practices from key opinion leaders. Sign up.
Hear experiences from some of the first Omnipod® 5 Podders®
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Mean HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, P<0.0001; 7.67% vs 6.99%, P<0.0001, respectively. Study funded by Insulet.
2. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05. Study funded by Insulet.